Form 4: BridgeBio Pharma Executive Reports Stock Transaction
Insider Transaction (Form 4)
Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., reported a transaction in 4,714 shares of common stock on August 16, 2026.
Summary
- Tax/exercise-price withholding: disposed of 4,714 Common Stock at $79.86 ($376,460) on August 16, 2026; holds 122,687 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Maricel Apuli — Officer (Chief Accounting Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-16 | Tax/exercise-price withholding | Common Stock | 4,714 | $80 | $376.5K | 122,687 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-16 | Tax/exercise-price withholding (4,714 shares) |
Keywords
insider transaction, Form 4, BBIO, BridgeBio Pharma, Inc., neutral, Maricel Apuli
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.